Segraves Robert Taylor, Balon Richard
Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA; Department of Anesthesiology, Wayne State University School of Medicine, Detroit, MI, USA.
Pharmacol Biochem Behav. 2014 Jun;121:132-7. doi: 10.1016/j.pbb.2013.11.003. Epub 2013 Nov 15.
Most of the available antidepressant medications, including tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, and dual noradrenergic/serotonergic reuptake inhibitors have been reported to be associated with sexual dysfunction in both sexes. This manuscript reviews evidence concerning the relative incidence of treatment emergent sexual dysfunction in men being treated with antidepressant drugs. Both double-blind controlled trials and large clinical series report a high incidence of sexual dysfunction, especially ejaculatory delay, with serotonergic drugs. The incidence of sexual dysfunction in men appears to be much lower with drugs whose primary mechanism of action involves adrenergic or dopaminergic systems.
大多数现有的抗抑郁药物，包括三环类抗抑郁药、单胺氧化酶抑制剂、选择性5-羟色胺再摄取抑制剂以及双重去甲肾上腺素能/5-羟色胺再摄取抑制剂，均已被报道与两性的性功能障碍有关。本论文综述了关于接受抗抑郁药物治疗的男性中治疗引发性功能障碍的相对发生率的证据。双盲对照试验和大型临床系列研究均报告，使用5-羟色胺能药物时性功能障碍的发生率很高，尤其是射精延迟。对于主要作用机制涉及肾上腺素能或多巴胺能系统的药物，男性性功能障碍的发生率似乎要低得多。
